David Kuter, MD, DPhil discusses Wayrilz™ (rilzabrutinib), a new FDA-approved treatment for persistent or chronic immune thrombocytopenia (ITP). Dr Kuter ...

Capvaxive was approved in 2024 for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae in adults.